{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:18:39Z","timestamp":1792811919191,"version":"4.5.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012615","name":"UTHealth Houston","doi-asserted-by":"publisher","award":["K24AI120834"],"award-info":[{"award-number":["K24AI120834"]}],"id":[{"id":"10.13039\/100012615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We previously reported reductions in weight and cardiometabolic risk factors in people with human immunodeficiency virus (PWH) receiving semaglutide; here, we explored the durability of these changes after treatment cessation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ACTG A5371 enrolled PWH \u226518 years on suppressive antiretroviral therapy with metabolic dysfunction\u2013associated steatotic liver disease. All received subcutaneous semaglutide 1\u2005mg weekly for 24 weeks followed by 24 weeks off semaglutide. We measured weight and cardiometabolic risk factors (blood pressure, cholesterol, metabolic syndrome) at weeks 0, 24, and 48. Mean (95% confidence interval [CI]) changes were estimated using linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 49 participants had a median age of 52 years, body mass index 35\u2005kg\/m2, 39% Hispanic and 33% Black, and 43% female. After the mean 7.8\u2005kg (95% CI, 6.1\u20139.5) weight loss in the first 24 weeks, absolute mean weight regain from 24 to 48 weeks was +2.9\u2005kg (95% CI, 1.5-4.3). Weight regain was accompanied by significant increases in waist circumference (2.0\u2005cm [0.9-3.1]) and fasting glucose (5.1\u2005mg\/dL [0.9-9.3]) without significant changes in blood pressure, total or low-density lipoprotein cholesterol, triglycerides, or metabolic syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Short-term, low-dose, semaglutide was associated with cardiometabolic benefit in PWH, but rapid weight regain and some loss of cardiometabolic benefit occurred after stopping semaglutide, similar to the general population. Further study of higher dose semaglutide and strategies to maintain benefits following initial therapy are needed in PWH.<\/jats:p>\n                    <jats:p>ClinicalTrials.gov: NCT04216589<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf652","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:50:29Z","timestamp":1764075029000},"page":"e544-e548","source":"Crossref","is-referenced-by-count":6,"title":["The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0808-6729","authenticated-orcid":false,"given":"Kristine M","family":"Erlandson","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W","family":"Kitch","sequence":"additional","affiliation":[{"name":"Harvard TH Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kantor","sequence":"additional","affiliation":[{"name":"Harvard TH Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo F","family":"Belaunzaran-Zamudio","sequence":"additional","affiliation":[{"name":"Contractor for National Institute of Allergy and Infectious Diseases , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8599-278X","authenticated-orcid":false,"given":"Todd T","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6778-7253","authenticated-orcid":false,"given":"Carl J","family":"Fichtenbaum","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cincinnati , Cincinnati, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya L","family":"Heath","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alabama Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred R","family":"Sattler","sequence":"additional","affiliation":[{"name":"Deparment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-5514","authenticated-orcid":false,"given":"Jordan E","family":"Lake","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UTHealth , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"2026031619524512100_ciaf652-B1","doi-asserted-by":"crossref","first-page":"e029282","DOI":"10.1161\/JAHA.122.029282","article-title":"Role of glucagon-like peptide-1 receptor agonists in achieving weight loss and improving cardiovascular outcomes in people with overweight and obesity","volume":"12","author":"Michos","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026031619524512100_ciaf652-B2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/cells13010065","article-title":"GLP1 receptor agonists\u2013effects beyond obesity and diabetes","volume":"13","author":"Wilbon","year":"2023","journal-title":"Cells"},{"key":"2026031619524512100_ciaf652-B3","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026031619524512100_ciaf652-B4","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"2026031619524512100_ciaf652-B5","doi-asserted-by":"crossref","first-page":"e13929","DOI":"10.1111\/obr.13929","article-title":"Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis","volume":"26","author":"Berg","year":"2025","journal-title":"Obes Rev"},{"key":"2026031619524512100_ciaf652-B6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1210\/endrev\/bnad028","article-title":"Adipose tissue dysfunction and energy balance paradigms in people living with HIV","volume":"45","author":"Ramirez Bustamante","year":"2024","journal-title":"Endocr Rev"},{"key":"2026031619524512100_ciaf652-B7","first-page":"75","article-title":"Fatty liver disease in persons with HIV infection","volume":"27","author":"Seth","year":"2019","journal-title":"Top Antivir Med"},{"key":"2026031619524512100_ciaf652-B8","doi-asserted-by":"crossref","first-page":"835","DOI":"10.7326\/M23-3354","article-title":"The effect of open-label semaglutide on metabolic dysfunction-associated steatotic liver disease in people with HIV","volume":"177","author":"Lake","year":"2024","journal-title":"Ann Intern Med"},{"key":"2026031619524512100_ciaf652-B9","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"2026031619524512100_ciaf652-B10","doi-asserted-by":"crossref","first-page":"e13336","DOI":"10.14814\/phy2.13336","article-title":"Composition of two-week change in body weight under unrestricted free-living conditions","volume":"5","author":"Bhutani","year":"2017","journal-title":"Physiol Rep"},{"key":"2026031619524512100_ciaf652-B11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13679-023-00534-z","article-title":"The role of lifestyle modification with second-generation anti-obesity medications: comparisons, questions, and clinical opportunities","volume":"12","author":"Wadden","year":"2023","journal-title":"Curr Obes Rep"},{"key":"2026031619524512100_ciaf652-B12","doi-asserted-by":"publisher","DOI":"10.1177\/15598276251344827","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"2026031619524512100_ciaf652-B13","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"key":"2026031619524512100_ciaf652-B14","doi-asserted-by":"crossref","first-page":"110875","DOI":"10.1016\/j.exger.2020.110875","article-title":"Impact of calorie restriction on energy metabolism in humans","volume":"133","author":"Most","year":"2020","journal-title":"Exp Gerontol"},{"issue":"9):","key":"2026031619524512100_ciaf652-B15","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2337\/dc25-1082","article-title":"Benefit of semaglutide in symptomatic peripheral artery disease by baseline type 2 diabetes characteristics: insights from STRIDE, a randomized, placebo-controlled, double-blind trial","volume":"48","author":"Rasouli","year":"2025","journal-title":"Diabetes Care"},{"issue":"7):","key":"2026031619524512100_ciaf652-B16","doi-asserted-by":"crossref","first-page":"930","DOI":"10.7326\/ANNALS-24-00775","article-title":"Comparison of semaglutide or dulaglutide versus empagliflozin for risk for death and cardiovascular outcomes among patients with type 2 diabetes: two target trial emulation studies","volume":"178","author":"Saeed","year":"2025","journal-title":"Ann Intern Med"},{"key":"2026031619524512100_ciaf652-B17","first-page":"1024","article-title":"Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease","volume":"82","author":"Go","year":"2025","journal-title":"J Vasc Surg"},{"key":"2026031619524512100_ciaf652-B18","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"2026031619524512100_ciaf652-B19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40256-025-00721-4","article-title":"Cardiovascular effects of semaglutide in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"25","author":"Sobral","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026031619524512100_ciaf652-B20","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1038\/s41467-025-59616-2","article-title":"Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study","volume":"16","author":"Lin","year":"2025","journal-title":"Nat Commun"},{"key":"2026031619524512100_ciaf652-B21","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.jacc.2025.03.516","article-title":"Effects of tirzepatide in type 2 diabetes: individual variation and relationship to cardiometabolic outcomes","volume":"85","author":"Aminorroaya","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026031619524512100_ciaf652-B22","doi-asserted-by":"crossref","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026031619524512100_ciaf652-B23","doi-asserted-by":"crossref","first-page":"1366940","DOI":"10.3389\/fendo.2024.1366940","article-title":"The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study","volume":"15","author":"Jensterle","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026031619524512100_ciaf652-B24","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1111\/dom.70096","article-title":"Treat to target in weight management with semaglutide: real-world evidence from an eHealth clinic","volume":"27","author":"Seier","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"7):","key":"2026031619524512100_ciaf652-B25","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/oby.24302","article-title":"Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy","volume":"33","author":"Wu","year":"2025","journal-title":"Obesity (Silver Spring)"},{"key":"2026031619524512100_ciaf652-B26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2337\/cd23-0023","article-title":"Special report: potential strategies for addressing GLP-1 and dual GLP-1\/GIP receptor agonist shortages","volume":"41","author":"Whitley","year":"2023","journal-title":"Clin Diabetes"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf652\/65552798\/ciaf652.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/3\/e544\/65552798\/ciaf652.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/3\/e544\/65552798\/ciaf652.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:52:58Z","timestamp":1773705178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/3\/e544\/8343661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,26]]},"published-print":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf652","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,15]]},"published":{"date-parts":[[2025,11,26]]}}}